Fecal osteoprotegerin may guide the introduction of second‐line therapy in hospitalized children with ulcerative colitis

• Published in: Inflammatory bowel diseases Vol. 17; no. 8; pp. 1726 - 1730
• Main Authors: Sylvester, Francisco A., Turner, Dan, Draghi, Andrew, Uuosoe, Krista, McLernon, Robin, Koproske, Kristen, Mack, David R., Crandall, Wallace V., Hyams, Jeffrey S., LeLeiko, Neal S., Griffiths, Anne M.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2011
• Subjects: Adolescent; Adrenal Cortex Hormones - therapeutic use; Apoptosis; Biomarkers - analysis; Child; Child, Preschool; Children; Colectomy; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - metabolism; Colitis, Ulcerative - surgery; Corticoids; corticosteroids; Feces - chemistry; Female; Hospitalization; Humans; Immunoregulation; Inflammation; Inflammatory bowel diseases; infliximab; Intestine; Intravenous administration; lactoferrin; Male; Monoclonal antibodies; Mucosa; Osteoprotegerin; Osteoprotegerin - analysis; Osteoprotegerin - metabolism; Pediatrics; Predictive Value of Tests; ROC Curve; Severity of Illness Index; Time Factors; Treatment Failure; Tumor necrosis factor- alpha; Ulcerative colitis
• ISSN: 1078-0998; 1536-4844; 1536-4844
• DOI: 10.1002/ibd.21561

Background: Osteoprotegerin (OPG) is increased in inflamed colonic mucosa and has a role in immune regulation and apoptosis resistance. Fecal OPG may be useful in predicting corticosteroid resistance in hospitalized children with severe ulcerative colitis (UC). We aimed to determine whether fecal OPG predicts the need for second‐line therapies in children hospitalized for UC. Methods: We included 83 children with UC admitted for intravenous corticosteroid treatment. Children were classified as responders/nonresponders based on the need for therapy escalation. Fecal OPG results were compared with those of four other fecal markers. Results: Of the enrolled children, seven had day 1 samples only, 53 children had day 3 samples only, and 23 had both. Twenty‐two children failed corticosteroid therapy and required infliximab (n = 20) or colectomy (n = 2). On the third treatment day the median fecal OPG levels were significantly higher in the nonresponders group compared with the responders: 77 pmol/L (interquartile range [IQR] 27–137) versus 13 pmol/L (3–109); P = 0.007. The best day 3 fecal OPG cutoff to predict second‐line therapy was >50 pmol/L with a sensitivity of 71% and specificity of 69% (area under the receiver operator curve [ROC] of 0.70%–95% confidence interval [CI] 0.57–0.82). Fecal OPG was superior to day 3 fecal calprotectin, lactoferrin, and S100A12 as a predictor of corticosteroid nonresponse, but equivalent to the less commonly used M2‐pyruvate kinase. Conclusions: Day 3 fecal OPG may guide the decision to institute second‐line therapy in children with severe UC. The role of OPG in the inflammatory response in pediatric UC deserves further study. (Inflamm Bowel Dis 2010;)